Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Looks good to me

<< Previous

Bullboard Posts

Next >>

Comment by Stockmoneyman17on Dec 05, 2020 9:30am

151 Views

Post# 32043567

RE:RE:Looks good to me

Also look up Jed wood. He was a director for Hemo back in 2016, same time as Kyle Makofka You think these boys don't no anything about the product Hemo has? This was the group who tried to take it over

IMO

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market